ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

praliciguat

Also written as “IW-1973”, “Praliciguat (Part A)” and “Praliciguat (Part B)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Glomerulosclerosis, Focal Segmental · Heart Failure, led by 2 companies.

Drug pagePraliciguat: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 15, 20168 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ironwood Pharmaceuticalsits history only50 open or runningphase 2since Sep 15, 2016Oct 29, 2015none ahead
Akebia Therapeutics31 open or runningphase 2since Jul 12, 2017Jul 12, 2017Jun 2027phase 2 · NCT07268638

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Akebia Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named praliciguatINNProposed as its International Nonproprietary Name in WHO's List 116 · before, IW-1973
  2. Jul 12, 2017First study: phase 2 study in Type 2 Diabetes Mellitus With Diabetic NephropathyFirst studyNCT03217591 · 156 enrolled · United States
  3. Aug 16, 2017Phase 2 study in Heart FailureNCT03254485 · 196 enrolled · United States, Canada
  4. Nov 26, 2025Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT07268638 · 60 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT07268638

TargetBeta

“Soluble guanylate cyclase activator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
Nitroglycerinrulemediquest-therapeuticsphase 414
ataciguatruleSanofiphase 33

Studies

All 3 Akebia Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07268638Glomerulosclerosis, Focal Segmental · United States2RecruitingJun 202760
NCT03254485Heart Failure · United States, Canada2CompletedAug 19, 2019196
NCT03217591Type 2 Diabetes Mellitus With Diabetic Nephropathy · United States2CompletedAug 20, 2019156

How it is read

Names in the registry

  • “IW-1973”, 7 entries
  • “Praliciguat (Part A)”, 1 entry
  • “Praliciguat (Part B)”, 1 entry
  • “[14C]-praliciguat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.